Provided by Tiger Fintech (Singapore) Pte. Ltd.

Organon & Co

10.57
+0.12001.15%
Post-market: 10.56-0.0114-0.11%16:12 EDT
Volume:3.52M
Turnover:37.21M
Market Cap:2.75B
PE:3.93
High:10.70
Open:10.43
Low:10.33
Close:10.45
52wk High:20.09
52wk Low:8.01
Shares:259.97M
Float Shares:258.73M
Volume Ratio:0.66
T/O Rate:1.36%
Dividend:0.60
Dividend Rate:5.68%
EPS(TTM):2.69
EPS(LYR):3.36
ROE:159.64%
ROA:6.62%
PB:3.75
PE(LYR):3.14

Loading ...

Stock Track | Organon & Co Soars 7.30% on Strong Q1 Performance and Restructuring Plans

Stock Track
·
May 02

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Wayfair, Moderna

Reuters
·
May 02

Organon Shares Fall After Lower Q1 Adjusted Earnings, Revenue

MT Newswires Live
·
May 01

Stock Track | Organon Plummets 24.48% as Q1 Earnings Disappoint and Dividend Slashed

Stock Track
·
May 01

Stock Track | Organon & Co Plummets 24.48% as Q1 Results Disappoint and Dividend Slashed

Stock Track
·
May 01

Organon & Co reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 01

Organon Shares Tumble on Cut Dividend, Weaker 1Q Results

Dow Jones
·
May 01

Top Premarket Decliners

MT Newswires Live
·
May 01

Organon Q1 2025 Adj. EPS $1.02 Beats $0.90 Estimate, Sales $1.51B Inline

Benzinga
·
May 01

Organon & Co. Reports Q1 2025 Results: Sales Down 7%, Adjusted EPS at $1.02, Net Income Falls to $87 Million

Reuters
·
May 01

BRIEF-Organon Q1 Adjusted EPS USD 1.02 Vs. IBES Estimate USD 0.9

Reuters
·
May 01

BofA Securities Adjusts Price Target on Organon to $11 From $15, Maintains Underperform Rating

MT Newswires Live
·
Apr 21

BRIEF-Organon & Co - Expects $6 Million Milestone Expense In Q1 2025

Reuters
·
Apr 15

Press Release: Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

Dow Jones
·
Apr 15

Organon Acquires Tofidence for Intravenous Infusion in US

MT Newswires Live
·
Apr 01

Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug

MT Newswires Live
·
Mar 28

BRIEF-European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX11

Reuters
·
Mar 28